Glycosaminoglycan-dnase combination therapy
CA 2516322 C · Owner: Shute, Janis · Inventors: Shute, Janis Kay; Hockey, Peter Morey; Carroll, Mary Patricia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of improving the efficacy of the treatment with a DNase of a subject having a disorder characterised by the presence of endogenous extracellular DNA, comprises : (a) administering to the subject a glycosaminoglycan or a physiologically acceptable salt thereof the glycosaminoglycan or salt having , an average molecular weight of from 8 to 40kd to the subject; and (b) administering DNase to the subject.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 14, 2003 and granted October 15, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 14, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 14, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.